Cytokinetics, Incorporated - Common Stock (NQ:CYTK)

80.62 UNCHANGED

Streaming Delayed Price Updated: 4:00 PM EDT, Jul 27, 2026 Add to My Watchlist

Price and Volume

Volume	285
Open	80.62
Bid (Size)	80.16 (100)
Ask (Size)	81.22 (100)
Prev. Close	80.62
Today's Range	80.62 - 80.62
52wk Range	32.89 - 88.31
Shares Outstanding	95,640,600
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Prediction: U.S. Small-Cap Stocks Will Beat Large Caps for 10 Years ↗

July 21, 2026

If you want to lock in future gains from today's small-cap stocks, these two ETFs could be good options.

Via The Motley Fool

What This Cytokinetics Insider Sale Might Mean With the Stock Up 110% ↗

July 14, 2026

Blum exercised options at $10.60 per share and immediately sold them at $82.02, capturing gains from a 122% stock surge over the past year. He retains 381,986 shares and maintains a 0.31% ownership...

Via The Motley Fool

Performance

YTD	+30.6%	+30.6%
1 Month	-7.6%	-7.6%
3 Month	+30.9%	+30.9%
6 Month	+27.6%	+27.6%
1 Year	+120.1%	+120.1%

More News

Cytokinetics Says MYKORZO Launch Tops Expectations as HCM Data Draws Praise ↗

May 22, 2026

Via MarketBeat

Cytokinetics Inc. (NASDAQ:CYTK) Scores Strong Setup Quality for a Potential Breakout ↗

April 23, 2026

Via Chartmill

Cytokinetics Inc (NASDAQ:CYTK) Reports Strong Q4 Revenue Beat Amid Deepening Losses and Negative Market Reaction ↗

February 24, 2026

Via Chartmill

CYTOKINETICS INC (NASDAQ:CYTK) Shows Strong Technicals and High-Quality Breakout Setup ↗

February 14, 2026

Via Chartmill

Cytokinetics (CYTK) Q1 2026 Earnings Transcript ↗

May 05, 2026

Via The Motley Fool

Wondering what's happening in today's pre-market session? ↗

May 05, 2026

Via Chartmill

Biohaven Stock Down 70% but One Fund's New $6 Million Bet Signals Turnaround Potential ↗

March 23, 2026

Via The Motley Fool

This Biotech Stock Winner Is Up 72%, but a $4 Million Trim Signals a Slight Reset ↗

March 21, 2026

Via The Motley Fool

This $6.5 Million Healthcare Trim Comes Amid a 71% Stock Surge and 20% Revenue Growth ↗

March 21, 2026

Via The Motley Fool

This $8.9 Million Buy Targets a Stock Down 68% With $322 Million in Cash ↗

March 21, 2026

Via The Motley Fool

DAFNA Capital Trims iShares Biotechnology ETF Within Broader Biotech Portfolio, According to Recent SEC Filing ↗

March 21, 2026

Via The Motley Fool

This $91 Million Position Signals Conviction in a Biotech Stock Eyeing FDA Decision This Year ↗

March 20, 2026

Via The Motley Fool

Cytokinetics Insider Exercises Options Worth Over $920,000 as Heart Drug Hits the Market ↗

March 09, 2026

Via The Motley Fool

Cytokinetics (CYTK) Q4 2025 Earnings Transcript ↗

February 24, 2026

Via The Motley Fool

European Commission Grants Marketing Authorization to Cytokinetics for Cardiac Drug MYQORZO

February 23, 2026

Via MarketMinute

Cytokinetics Secures Triple Crown: EU Approval of MYQORZO Solidifies Global Reach in Cardiovascular Market

February 19, 2026

Via MarketMinute

The Law Offices of Frank R. Cruz Announces Investigation of Cytokinetics, Incorporated (CYTK) on Behalf of Investors

January 22, 2026

From The Law Offices of Frank R. Cruz

Via Business Wire

The $5.1 Trillion Wave: Why 2026 is Set to Become the Biggest Year for Global M&A

January 16, 2026

Via MarketMinute

Important Notice to Long-Term Shareholders of Cytokinetics, Inc. (NASDAQ: CYTK); Lifecore Biomedical, Inc. (NASDAQ: LFCR); Molina Healthcare, Inc. (NYSE: MOH); and Synopsys, Inc. (NASDAQ: SNPS): Grabar Law Office Investigates Claims on Your Behalf

January 08, 2026

From Grabar Law Office

Via GlobeNewswire

Notice to Long-Term Shareholders of Cytokinetics, Inc. (NASDAQ: CYTK); Lifecore Biomedical, Inc. (NASDAQ: LFCR); Molina Healthcare, Inc. (NYSE: MOH); and WEBTOON Entertainment, Inc. (NASDAQ: WBTN): Grabar Law Office Investigates Claims on Your Behalf

January 07, 2026

From Grabar Law Office

Via GlobeNewswire

The Great Rebalancing: Small-Caps Surge as Big Tech Giants Stumble in Early 2026

January 02, 2026

Via MarketMinute

January 02, 2026

From Grabar Law Office

Via GlobeNewswire

Biotech’s Resurgence: How a Year-End Rally and M&A Frenzy Set the Stage for 2026

December 31, 2025

Via MarketMinute

Frequently Asked Questions

Is Cytokinetics, Incorporated - Common Stock publicly traded?

Yes, Cytokinetics, Incorporated - Common Stock is publicly traded.

What exchange does Cytokinetics, Incorporated - Common Stock trade on?

Cytokinetics, Incorporated - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Cytokinetics, Incorporated - Common Stock?

The ticker symbol for Cytokinetics, Incorporated - Common Stock is CYTK on the Nasdaq Stock Market

What is the current price of Cytokinetics, Incorporated - Common Stock?

The current price of Cytokinetics, Incorporated - Common Stock is 80.62

When was Cytokinetics, Incorporated - Common Stock last traded?

The last trade of Cytokinetics, Incorporated - Common Stock was at 07/27/26 04:00 PM ET

What is the market capitalization of Cytokinetics, Incorporated - Common Stock?

The market capitalization of Cytokinetics, Incorporated - Common Stock is 7.71B

How many shares of Cytokinetics, Incorporated - Common Stock are outstanding?

Cytokinetics, Incorporated - Common Stock has 8B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.